EJC Supplements
Volume 5, Issue 2 , Pages 13-22 , July 2007

The need for aminoglycosides in combination with β-lactams for high-risk, febrile neutropaenic patients with leukaemia

  • Lubos Drgona

      Affiliations

    • Department of Internal Medicine, National Cancer Institute, Bratislava, Slovakia
    • ,
  • Mical Paul

      Affiliations

    • Department of Medicine E, Rabin Medical Center, Beilinson Hospital, Petah Tikva, Israel
    • Corresponding Author InformationCorresponding author: Tel.: +972 3 9376504; fax: +972 3 9376512.
    • ,
  • Giampaolo Bucaneve

      Affiliations

    • Department of Internal Medicine, Ospedale Silvestrini, Perugia, Italy
    • ,
  • Thierry Calandra

      Affiliations

    • Infectious Diseases Service, Department of Medicine, Centre Hospitalier Universitaire Vaudois, University of Lausanne, CH-1011 Lausanne, Switzerland
    • ,
  • Francesco Menichetti

      Affiliations

    • Infectious Diseases Unit, Ospedale Cisanello, Pisa, Italy

Received 14 May 2007 ,Revised 6 June 2007 ,Accepted 11 June 2007.

References 

  1. Schimpff S, Satterlee W, Young VM, et al. Empiric therapy with carbenicillin and gentamicin for febrile patients with cancer and granulocytopenia. N Engl J Med. 1971;284:1061–1065
  2. Schimpff SC. Empiric antibiotic therapy for granulocytopenic cancer patients. Am J Med. 1986;80:13–20
  3. Hughes WT, Armstrong D, Bodey GP, et al. From the Infectious Diseases Society of America. Guidelines for the use of antimicrobial agents in neutropaenic patients with unexplained fever. J Infect Dis. 1990;161:381–396
  4. Hughes WT, Armstrong D, Bodey GP, et al. guidelines for the use of antimicrobial agents in neutropaenic patients with unexplained fever. Infectious Diseases Society of America. Clin Infect Dis. 1997;25:551–573
  5. Klastersky J, Paesmans M, Rubenstein EB, et al. The Multinational Association for Supportive Care in Cancer risk index: a multinational scoring system for identifying low-risk febrile neutropaenic cancer patients. J Clin Oncol. 2000;18:3038–3051
  6. Talcott JA, Siegel RD, Finberg R, et al. Risk assessment in cancer patients with fever and neutropaenia: a prospective, two-centre validation of a prediction rule. J Clin Oncol. 1992;10:316–322
  7. Vidal L, Paul M, Ben dor I, et al. Oral versus intravenous antibiotic treatment for febrile neutropaenia in cancer patients: a systematic review and meta-analysis of randomized trials. J Antimicrob Chemother. 2004;54:29–37
  8. Ramphal R. Changes in the etiology of bacteraemia in febrile neutropaenic patients and the susceptibilities of the currently isolated pathogens. Clin Infect Dis. 2004;9(Suppl. 1):S25–S31
  9. Hughes WT, Armstrong D, Bodey GP, et al. guidelines for the use of antimicrobial agents in neutropaenic patients with cancer. Clin Infect Dis. 2002;34:730–751
  10. Paul M, Soares-Weiser K, Grozinsky S, et al. Beta-lactam versus beta-lactam-aminoglycoside combination therapy in cancer patients with neutropaenia. Cochrane Database Syst Rev. 2003;2:CD003038
  11. Furno P, Bucaneve G, Del Favero A. Monotherapy or aminoglycoside-containing combinations for empirical antibiotic treatment of febrile neutropaenic patients: a meta-analysis. Lancet Infect Dis. 2002;2:231–242
  12. Wrzesien-Kus AJ, Wierzbowska K, Robak AT. Cefepine in monotherapy or in combination with amikacine as the empirical treatment of febrile neutropaenic patients. Acta Haematol Pol. 2001;32:165–172
  13. Kliasova G, Savchenko VLL, Mendeleeva L, et al. (Moscow, RUS). Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empiric therapy for febrile neutropaenic bone marrow transplant patients. In: 11th European Congress of clinical microbiology and infectious diseases; 2001.
  14. Kiehl MG, Bischoff M, Basara N, et al. A prospective randomized trial comparing the efficacy and safety of piperacillin/tazobactam versus piperacillin/tazobactam plus netilmicin in the treatment of febrile neutropenia in allogeneic stem cell recipients. In: 41st interscience conference on antimicrobial agents and chemotherapy. Chicago. Americal Society for Microbiology; 2001;p. 267
  15. Bru JP, Michallet M, Legrand C, et al. A prospective randomized study comparing the efficacy of Timentin alone or in combination with amikacin in the treatment of febrile neutropaenic patients. J Antimicrob Chemother. 1986;17(Suppl. C):203–209
  16. Bilgir O, Kadikoylu V, Bilgir F. The comparison of imipenem with piperacillin/tazobactam and amikacin combination in patients with haematological malignancies in the treatment of febrile neutropaenia. In: 10th Congress of the European haematology association, Stockholm, Sweden; 2005 [abstract no. 1021].
  17. Gaytan-Martinez JE, Mateos-Garcia E, Casanova LJ, et al. Efficacy of empirical therapy with cefepime compared with ceftazidime plus amikacin in febrile neutropaenic patients. In: Annual meeting of the American society of haematology; 2002 [abstract no. 3655].
  18. Gorschluter M, Hahn C, Fixson A, et al. Piperacillin-tazobactam is more effective than ceftriaxone plus gentamicin in febrile neutropaenic patients with haematological malignancies: a randomized comparison. Support Care Cancer. 2003;11:362–370
  19. Miller JA, Butler T, Beveridge RA, et al. Efficacy and tolerability of imipenem-cilastatin versus ceftazidime plus tobramycin as empiric therapy of presumed bacterial infection in neutropaenic cancer patients. Clin Ther. 1993;15:486–499
  20. Tamura K, Imajo K, Akiyama N, et al. Randomized trial of cefepime monotherapy or cefepime in combination with amikacin as empirical therapy for febrile neutropaenia. Clin Infect Dis. 2004;39(Suppl. 1):S15–S24
  21. Antmen B, Sasmaz I, Tanyeli A et al. Initial empiric antibiotic treatments in childhood febrile neutropaenia: meropenem versus ceftazidime plus amikacin combination. In: 11th European congress of clinical microbiology and infectious diseases; 2001.
  22. Corapcioglu F, Sarper N. Cefepime versus ceftazidime + amikacin as empirical therapy for febrile neutropaenia in children with cancer: a prospective randomized trial of the treatment efficacy and cost. Pediatr Haematol Oncol. 2005;22:59–70
  23. El Haddad A. Comparison of cefoperazone-sulbactam versus piperacillin plus amikacin as empiric therapy in pediatric febrile neutropaenic cancer patients. Curr Therapeut Res Clin Exp. 1995;56:1094–1099
  24. Hung KC, Chiu HH, Tseng YC, et al. Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empirical therapy for neutropaenic fever in children with malignancy. J Microbiol Immunol Infect. 2003;36:254–259
  25. Koehler M, Bubala H, Sonta-Jakimczyk D, et al. Assessment of the efficacy of treating infections in haematopoietic proliferative diseases: Monotherapy with ceftazidime and tobramycin combined with amoxycillin/ampicillin [in Polish]. Pol Tyg Lek. 1990;45:417–420
  26. Petrilli AS, Cypriano M, Dantas LS, et al. Evaluation of ticarcillin/clavulanic acid versus ceftriaxone plus amikacin for fever and neutropaenia in pediatric patients with leukaemia and lymphoma. Braz J Infect Dis. 2003;7:111–120
  27. Ahmed-El Borollosy N, El Beshlawy A, El Mahallawy H, et al. Outpatient single dose ceftriaxone and amikacin versus imipenem/cilastatin monotherapy in the empiric treatment of pediatric patients with high risk fever and neutropenia. A randomized, prospective clinical trial. In: American society of haematology annual meeting abstracts; 2003.
  28. Ahmed-El Borollosy N, El Beshlawy A, El Mahallawy H, et al. Outpatient single dose ceftriaxone and amikacin versus imipenem/cilastatin monotherapy in the empiric treatment of pediatric patients with high risk fever aneutropaenia. A randomized, prospective clinical trial. In: American society of clinical oncology conference; 2004.
  29. Jimeno A, Arcediano A, Gomez C et al. Randomized study of cefepime versus ceftazidime plus amikacin in febrile neutropaenic patients with solid tumors treated with high dose chemotherapy and peripheral blood stem cell support. In: Proceedings of the American society of clinical oncology; 2003 [abstract no. 3387].
  30. Rodriguez W, Gomez H, Silva ME, et al. Cefotaxima versus cefalotina-gentamicina en el primer episodio febril de pacientes con tumores solidos y neutropaenia de corta duracion / Cefotaxime vs Cephalotin-Gentamicin in the first febrile episode of patients having solid tumors and short-term neutropaenia. Acta Cancerol. 1995;25:61–68
  31. Berezin EN, Almeida FJ, Santos AG et al. Asessment of Cefepime monotherapy versus combined therapy with ceftriaxone and aminoglicosyde in oncologic children and adolescents with febrile neutropaenia. In: 13th European congress of clinical microbiology and infectious diseases; 2003.
  32. Sanz MA, Bermudez A, Rovira M, et al. Imipenem/cilastatin versus piperacillin/tazobactam plus amikacin for empirical therapy in febrile neutropaenic patients: results of the COSTINE study. Curr Med Res Opin. 2005;21:645–655
  33. Caldas J, Fernandes T, Monteiro A et al. Management of febrile neutropaenia: single agent or combination therapy. In: American society of haematology annual meeting abstracts; 2004 [abstract no. 5063].
  34. Badea M, Badea D. Ceftriaxone in febrile granulocytopenic patients with haematological malignancies. In: European haematology association conference; 2002 [abstract no. 707].
  35. Akin H, Korten V, Akan H et al. Cefepime combined with a short (four days) or long course of isepamicin for empirical therapy of high-risk febrile neutropaenic haematological cancer patients: a prospective, randomised, multicentre study. In: European congress of clinical microbiology and infectious diseases; 2005 [abstract no. R2061].
  36. Fainstein V, Bodey GP, Elting L, et al. A randomized study of ceftazidime compared to ceftazidime and tobramycin for the treatment of infections in cancer patients. J Antimicrob Chemother. 1983;12(Suppl. A):101–110
  37. Sung L, Dupuis LL, Bliss B, et al. Randomized controlled trial of once- versus thrice-daily tobramycin in febrile neutropaenic children undergoing stem cell transplantation. J Natl Cancer Inst. 2003;95:1869–1877
  38. Ariffin H, Arasu A, Mahfuzah M, et al. Single-daily ceftriaxone plus amikacin versus thrice-daily ceftazidime plus amikacin as empirical treatment of febrile neutropaenia in children with cancer. J Paediatr Child Health. 2001;37:38–43
  39. Charnas R, Luthi AR, Ruch W. Once daily ceftriaxone plus amikacin versus three times daily ceftazidime plus amikacin for treatment of febrile neutropaenic children with cancer. Writing Committee for the International Collaboration on Antimicrobial Treatment of Febrile Neutropenia in Children. Pediatr Infect Dis J. 1997;16:346–353
  40. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer . Efficacy and toxicity of single daily doses of amikacin and ceftriaxone versus multiple daily doses of amikacin and ceftazidime for infection in patients with cancer and granulocytopenia. Ann Intern Med. 1993;119:584–593
  41. Rozdzinski E, Kern WV, Reichle A, et al. Once-daily versus thrice-daily dosing of netilmicin in combination with beta-lactam antibiotics as empirical therapy for febrile neutropaenic patients. J Antimicrob Chemother. 1993;31:585–598
  42. Gibson J, Johnson L, Snowdon L, et al. Single daily ceftriaxone and tobramycin in the empirical management of febrile neutropaenic patients: a randomised trial. Int J Haematol. 1993;58:63–72
  43. Torfoss D, Hoiby EA. Tobramycin once versus three times a day given with penicillin G to cancer patients with febrile neutropaenia: a prospective randomised multicentre trial. In: 16th European congress of clinical microbiology and infectious diseases. Nice, France. European Society of Clinical Microbiology and Infectious Diseases; 2006;p. 698
  44. Hansen MA, Carstensen F, Coolidge C, Dahlager J, Frimodt-Moller J. Once versus thrice-daily dosing of netilmicin in febrile immunocompromised patients: a randomized, controlled study of efficacy and safety. Journal of Drug Development. 1988;1(Suppl. 3):119–124
  45. Hatala R, Dinh TT, Cook DJ. Single daily dosing of aminoglycosides in immunocompromised adults: a systematic review. Clin Infect Dis. 1997;24:810–815
  46. Ali MZ, Goetz MB. A meta-analysis of the relative efficacy and toxicity of single daily dosing versus multiple daily dosing of aminoglycosides. Clin Infect Dis. 1997;24:796–809
  47. Bailey TC, Little JR, Littenberg B, et al. A meta-analysis of extended-interval dosing versus multiple daily dosing of aminoglycosides. Clin Infect Dis. 1997;24:786–795
  48. Barza M, Ioannidis JP, Cappelleri JC, et al. Single or multiple daily doses of aminoglycosides: a meta-analysis. BMJ. 1996;312:338–345
  49. Hatala R, Dinh T, Cook DJ. Once-daily aminoglycoside dosing in immunocompetent adults: a meta-analysis. Ann Intern Med. 1996;124:717–725
  50. Ferriols-Lisart R, Alos-Alminana M. Effectiveness and safety of once-daily aminoglycosides: a meta-analysis. Am J Health Syst Pharm. 1996;53:1141–1150
  51. Galloe AM, Graudal N, Christensen HR, et al. Aminoglycosides: single or multiple daily dosing? A meta-analysis on efficacy and safety. Eur J Clin Pharmacol. 1995;48:39–43
  52. Munckhof WJ, Grayson ML, Turnidge JD. A meta-analysis of studies on the safety and efficacy of aminoglycosides given either once daily or as divided doses. J Antimicrob Chemother. 1996;37:645–663
  53. Link H, Bohme A, Cornely OA, et al. Antimicrobial therapy of unexplained fever in neutropaenic patients–guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Haematology and Oncology (DGHO), Study Group Interventional Therapy of Unexplained Fever, Arbeitsgemeinschaft Supportivmassnahmen in der Onkologie (ASO) of the Deutsche Krebsgesellschaft (DKG-German Cancer Society). Ann Haematol. 2003;82(Suppl. 2):S105–S117
  54. NCCN. National Comprehensive Cancer Network. Clinical practice guidelines in oncology – fever and neutropenia. Available from: http://www.nccn.org/.
  55. Rolston KV, Bodey GP. Comment on: Empirical antibiotic monotherapy for febrile neutropenia: systematic review and meta-analysis of randomized controlled trials. J Antimicrob Chemother. 2006;58:478
  56. Paul M, Yahav D, Fraser A, et al. Empirical antibiotic monotherapy for febrile neutropaenia: systematic review and meta-analysis of randomized controlled trials. J Antimicrob Chemother. 2006;57:176–189
  57. Edwards SJ, Emmas CE, Campbell HE. Systematic review comparing meropenem with imipenem plus cilastatin in the treatment of severe infections. Curr Med Res Opin. 2005;21:785–794
  58. Viscoli C, Machetti M, Cappellano P, et al. False-positive galactomannan platelia Aspergillus test results for patients receiving piperacillin-tazobactam. Clin Infect Dis. 2004;38:913–916
  59. Safdar N, Handelsman J, Maki DG. Does combination antimicrobial therapy reduce mortality in Gram-negative bacteraemia? A meta-analysis. Lancet Infect Dis. 2004;4:519–527
  60. Klastersky J, Zinner SH, Calandra T, et al. Empiric antimicrobial therapy for febrile granulocytopenic cancer patients: lessons from four EORTC trials. Eur J Cancer Clin Oncol. 1988;24(Suppl. 1):S35–S45
  61. Cometta A, Zinner S, de Bock R, et al. Piperacillin-tazobactam plus amikacin versus ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. Antimicrob Agents Chemother. 1995;39:445–452
  62. Del Favero A, Menichetti F, Martino P, et al. A multicentre, double-blind, placebo-controlled trial comparing piperacillin-tazobactam with and without amikacin as empiric therapy for febrile neutropaenia. Clin Infect Dis. 2001;33:1295–1301
  63. Elting LS, Rubenstein EB, Rolston KV, et al. Outcomes of bacteraemia in patients with cancer and neutropaenia: observations from two decades of epidemiological and clinical trials. Clin Infect Dis. 1997;25:247–259
  64. Cornelissen JJ, de Graeff A, Verdonck LF, et al. Imipenem versus gentamicin combined with either cefuroxime or cephalothin as initial therapy for febrile neutropaenic patients. Antimicrob Agents Chemother. 1992;36:801–807
  65. Norrby SR, Vandercam B, Louie T, et al. Imipenem/cilastatin versus amikacin plus piperacillin in the treatment of infections in neutropaenic patients: a prospective, randomized multi-clinic study. Scand J Infect Dis. 1987;52(Suppl.):65–78
  66. Bliziotis IA, Samonis G, Vardakas KZ, et al. Effect of aminoglycoside and beta-lactam combination therapy versus beta-lactam monotherapy on the emergence of antimicrobial resistance: a meta-analysis of randomized, controlled trials. Clin Infect Dis. 2005;41:149–158

☆ The ECIL-1 is a common initiative of the following groups or organizations: Infectious Diseases Working Party of the European Blood and Marrow Transplantation Group (EBMT-IDWP), Infectious Diseases Group of the European Organization for Research and Treatment of Cancer (EORTC-IDG), European Leukaemia, Net (ELN) (EU Grant number: LSHC-CT-2004), and International Immunocompromised Host Society (ICHS).

PII: S1359-6349(07)00005-5

doi: 10.1016/j.ejcsup.2007.06.003

EJC Supplements
Volume 5, Issue 2 , Pages 13-22 , July 2007

Article Tools

* Image Usage & Resolution